Differential roles of phase I and phase II enzymes in 3,4- methylendioxymethamphetamine-induced cytotoxicity

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1105-1112

  Antolino Lobo, Irene ^a,b   Meulenbelt, Jan ^a,b,c   Nijmeijer, Sandra M ^a   Scherpenisse, Peter ^a   Van Den Berg, Martin ^a   Van Duursen, Majorie B M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA NAPHTHOFLAVONE; BUTHIONINE SULFOXIMINE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE; QUINIDINE; TROLEANDOMYCIN; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL IMMORTALIZATION; CYTOTOXICITY; DETOXIFICATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER TOXICITY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG DETOXIFICATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PHYSIOLOGY; TRANSFORMED CELL LINE;

RATTUS;

ANIMALS; CELL LINE, TRANSFORMED; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; MALE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MICROSOMES, LIVER; MODELS, BIOLOGICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS;

EID: 77953730403     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032359     Document Type: Article

References (36)

1. Akhter N, Tanaka S, Ashino T, Shima N, Katagi M, Tsuchihashi H, Mian AH, Numazawa S, and Yoshida T (2008) In vivo study on the roles of cytochrome P450 enzymes for metabolism of 3,4-methylenedioxymethamphetamine (Ecstasy) in rats. Forensic Toxicol 26:52-57.
2. Bolton JL, Trush MA, Penning TM, Dryhurst G, and Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135-160.
3. Carmo H, Brulport M, Hermes M, Oesch F, Silva R, Ferreira LM, Branco PS, Boer D, Remião F, Carvalho F, et al. (2006) Influence of CYP2D6 polymorphism on 3,4-methylenedioxymeth-amphetamine ('Ecstasy') cytotoxicity. Pharmacogenet Genomics 16:789-799.
4. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E, Carvalho F, and Bastos ML (2002) Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 76:581-588.
5. Carvalho M, Milhazes N, Remião F, Borges F, Fernandes E, Amado F, Monks TJ, Carvalho F, and Bastos ML (2004a) Hepatotoxicity of 3,4-methylenedioxyamphetamine and alphamethyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 78:16-24.
6. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Carvalho F, and Bastos ML (2004b) The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 200:193-203.
7. Cavin C, Mace K, Offord EA, and Schilter B (2001) Protective effects of coffee diterpenes against aflatoxin B1-induced genotoxicity: mechanisms in rat and human cells. Food Chem Toxicol 39:549-556.
8. de la Torre R, Farré M, Mathúna BO, Roset PN, Pizarro N, Segura M, Torrens M, Ortuño J, Pujadas M, and Camí J (2005) MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 61:551-554.
9. de la Torre R, Farre M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, and Camí J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109.
10. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144.
11. Donato MT, Jiménez N, Castell JV, and Gómez-Lechón MJ (2004) Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32:699-706.
12. EMCDDA (2008) Annual report, 2008: the state of the drugs problem in Europe. Luxembourg: Office for Official Publications of the European Communities. ISBN 978-92-9168-324-6, European Monitoring Center for Drugs and Drugs Addiction.
13. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
14. García-Repetto R, Moreno E, Soriano T, Jurado C, Giménez MP, and Menéndez M(2003) Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 135:110-114.
15. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, and Monks TJ (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422-431.
16. Kreth K, Kovar K, Schwab M, and Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59:1563-1571.
17. Lin LY, Kumagai Y, and Cho AK (1992) Enzymatic and chemical demethylenation of (methylenedioxy) amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem Res Toxicol 5:401-406.
18. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
19. Ma B, Prueksaritanont T, and Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125-130. (Pubitemid 30068994)
20. Malpass A, White JM, Irvine RJ, Somogyi AA, and Bochner F (1999) Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 64:29-34. (Pubitemid 29415793)
21. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142.
22. Meyer MR, Peters FT, and Maurer HH (2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy- methamphetamine and its enantiomers. Drug Metab Dispos 36:2345-2354.
23. Milhazes N, Cunha-Oliveira T, Martins P, Garrido J, Oliveira C, Rego AC, and Borges F (2006) Synthesis and cytotoxic profile of 3,4- methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: a putative structure-toxicity relationship. Chem Res Toxicol 19:1294-1304.
24. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136.
25. Nakagawa Y, Suzuki T, Tayama S, Ishii H, and Ogata A (2009) Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch Toxicol 83:69-80.
26. O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, et al. (2008) The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 28:523-529.
27. Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16:557-577.
28. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, and Sellers EM (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63:2111-2119.
29. Schifano F (2004) A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 173:242-248.
30. Schilt T, Koeter MW, de Win MM, Zinkstok JR, van Amelsvoort TA, Schmand B, and den Brink W (2009) The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene. Eur Neuropsychopharmacol 19:116-124.
31. Segura M, Farré M, Pichini S, Peiró AM, Roset PN, Ramírez A, Ortuño J, Pacifici R, Zuccaro P, Segura J, et al. (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44:649-660.
32. Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, et al. (2001) 3,4- Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14: 1203-1208.
33. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
34. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
35. Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J Psychopharmacol 20:834-841.
36. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, and Rostami-Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849.